BioSpace News Archive

S3 Process, an OEM specialising in process equipment for the pharmaceutical industry, is using BioPure BioClamp® and BioPure silicone gasket technology on its new PuroVaso® containers, for the effective handling of powders and tablets in life science applications.

Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.

For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.

D&D Pharmatech is the parent company of U.S.-based Neuraly, Precision Molecular and Theraly Fibrosis. All three are spinouts from Johns Hopkins School of Medicine.

Landos said the funds will be used to advance its lead asset, BT-11, into global Phase II clinical trials for ulcerative colitis and Crohn’s disease.

Frontage Clinical Services, Inc., an associate of Frontage Laboratories, Inc., is pleased to announce completion of renovations to Frontage Clinical’s center in Secaucus, New Jersey, to now accommodate clinical studies on tobacco and nicotine-containing products.

Virtually every aspect of what employers seek can be framed as an accomplishment – skills, values, experience, results, subject-matter knowledge, uniqueness, proof of performance.

Insilico Biotechnology AG and the Laboratory of Systems Theory and Automatic Control at the Institute for Automation Engineering of the Otto von Guericke University Magdeburg started a joint project on model predictive control for the production of monoclonal antibodies in mammalian cell culture processes using Insilico’s Digital Twins.

Ultragenyx Pharmaceutical Inc. and GeneTx Biotherapeutics LLC announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.

Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019.